Latest diarrhea Stories
Persistent bacterial infections can make a mess of our bowels and the usual treatment method of adding antibiotics usually causes even more disruptions. Researchers, however, are fine tuning a treatment that involves adding a sample of the stool of another which jump-starts the infected patients immune system, reports Kerry Grens for Reuters Health. The procedure is used primarily to treat patients with infections from the bacterium Clostridium difficile. “It’s unbelievably...
'When traveling in the tropics, my IBD felt the best ever,' recall patients Inflammatory bowel disease (IBD) travelers have an increased risk of illness during trips to industrialized countries, but not to developing or tropical regions, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association. "Inflammatory bowel disease patients are often advised to avoid travel, especially to the developing world....
PHILADELPHIA, January 10, 2012 /PRNewswire/ -- - Agreement allows development for potential treatment of chronic constipation Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor(R) (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V. Terms of the agreement have not been disclosed. Resolor, a prokinetic, is part of...
PHILADELPHIA, January 10, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor(R) (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V. Terms of the agreement have not been disclosed. Resolor, a prokinetic, is part of Shire's gastrointestinal (GI) portfolio in Europe and is approved for use in 33 countries...
EXTON, Pa., Jan. 5, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will provide an overview of the company's business during the 30th Annual J.P. Morgan Healthcare Conference. The presentation will be webcast live at 7:30 P.M. ET (4:30 P.M. PT) on Tuesday, January 10, 2012 and may be accessed via the company's website at www.viropharma.com. The conference is being...
The incidence and prevalence of inflammatory bowel disease (IBD) are increasing with time and in different regions around the world, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. "Insight into the worldwide epidemiology of inflammatory bowel disease is important for the identification of geographic patterns and time trends," said Gilaad G. Kaplan, MD, MPH, of the University of Calgary and lead author of this study. "Our...
LEXINGTON, Mass., Dec. 13, 2011 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company was awarded U.S. Patent 8,071,101, "Antibody Therapy for Treatment of Diseases Associated With Gluten Intolerance." This patent, which expires on May 27, 2029, provides broad coverage for treating celiac disease using orally administered antibodies produced by the...
SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Astellas Pharma Europe Ltd., a European subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) announced today that the European Commission has granted Marketing Authorization (MA) for DIFICLIR(TM) (fidaxomicin) tablets for the treatment of adults with Clostridium difficile infections (CDI) also known as Clostridium difficile-associated diarrhea (CDAD). CDI is a significant problem in...
LOS ANGELES, Dec. 9, 2011 /PRNewswire/ -- Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from ongoing Phase II clinical trials of Puma's investigational drug PB272 (neratinib) were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas. These presentations are further detailed below: Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients...
(Ivanhoe Newswire) – Clostridium difficile is the most common cause of infectious diarrhea in the hospital, and these infections increase the length of stay in the hospital by six days. Researchers used The Ottawa Hospital Data Warehouse to analyze data on 136,877 admissions to The Ottawa Hospital between July 1, 2002 and March 31, 2009. A total of 1393 patients acquired C. difficile in hospital during this time, and these patients spent 34 days in hospital compared with 8 days for...
Latest diarrhea Reference Libraries
Clostridium difficile, also known as "CDF/cdf", or "C. diff", is a Gram-positive bacteria of the genus Clostridium that causes severe diarrhea and other intestinal disease when competing bacteria in the gut flora are wiped out by antibiotics. They are anaerobic, spore-forming rods and is the most serious cause of antibiotic-associated diarrhea and potentially to pseudomembranous colitis. C. difficile bacteria naturally resides in the gut of a small percentage of the adult population. Others...
Rotavirus is the most common cause of diarrhea among infants and young children and is one of several viruses that cause the stomach flu. It is in the family Reoviridae and is a genus of double-stranded RNA. Most children have been infected by the age of five. Each infection builds on previous immunity and thus subsequent infections are less severe and adults are rarely affected. The fives species of the virus are referred to as A, B, C, D, and E. Type A, which is the most common, causes more...
Norovirus is an RNA virus that causes approximately 90% of epidemic non-bacterial outbreaks of gastroenteritis around the world. It may also be responsible for 50% of all foodborne outbreaks of gastroenteritis in the U.S. It can affect people of all ages and is transmitted by food or water that is contaminated, by person-to-person contact, and through aerosolization of the virus and subsequent contamination of surfaces. Immunity is usually incomplete and temporary after infection. People...
